ImmunoBiology Limited (ImmBio) Company Profile

05:08 EDT 19th September 2018 | BioPortfolio

Limited [ImmBio] is a biotechnology company specialising in the treatment of infectious diseases and cancer. ImmBio's approach is to apply advances in the emerging science of Immunobiology to the development of treatments for infections diseases and cancer.
Immbio is developing a proprietary vaccine technology based on these advances. The platform technology is called HspC™ vaccination.

HspC™ vaccination is designed to elicit a broad immune response that is specific to the chosen pathogen. HspC™ vaccination thus elicits a more powerful and longer lasting immune response than any alternate treatment regimes. Immbio will initially focus on treatments for infectious diseases (e.g. tuberculosis, influenza and hepatitis).

Dr Colaco set up Immbio in May 1999 to apply the principles of Immunobiology to the treatment of infectious diseases and cancer. In September 1999, ImmBio won a SMART award to begin development of a TB vaccine and this is the initial focus of the company. In 2003 ImmBio raised further funds to complete its TB PoP studies and begin an influenza vaccine programme


Babraham Bioincubator
United Kingdom


Phone: 44 (0) 1223 496116
Fax: 44 (0) 1223 496116

News Articles [29 Associated News Articles listed on BioPortfolio]

YCC launches new Yale Center for Immuno-Oncology

Yale Cancer Center has launched the Yale Center for Immuno-Oncology. The new center will build on YCC's international leadership in immunobiology, cancer immunology, and development of novel cancer im...

Quotient Limited Announces Details of Investor Day

JERSEY, Channel Islands, July 16, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced details of its investor day held at the NASDAQ he...

Quotient Limited to Host Investor Day on July 16, 2018

JERSEY, Channel Islands, June 18, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that it will host an Investor Day on Monday, July ...

Penn's E. John Wherry receives Stand Up to Cancer's Innovation in Collaboration Award

(University of Pennsylvania School of Medicine) E. John Wherry, PhD, co-leader of the Abramson Cancer Center's Immunobiology Program and director of the Institute for Immunology at the University of P...

Genetic Technologies Limited: Project Shivom Strategic Alliance

MELBOURNE, Australia, March 06, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG)  (NASDAQ:GENE) (“Company”, “GTG”) a diversified molecular diagnostics company; provider of...

Quotient Limited Announces Completion of Senior Secured Notes Offering

JERSEY, Channel Islands, July 02, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), has completed the offering of up to $120.0 million ...

Quotient Limited Reports Commencement of EU Blood Grouping Field Trial

JERSEY, Channel Islands, May 17, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported that it has completed the verification and validatio...

Quotient Limited appoints Franz Walt as Chief Executive Officer

JERSEY, Channel Islands, May 29, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the appointment of Franz Walt, as its Chief Executi...

PubMed Articles [21 Associated PubMed Articles listed on BioPortfolio]

Looking back on the alternative complement pathway.

The alternative pathway of complement originated from the Properdin pathway originally described by the Pillemer laboratory in the 1950s. This work generated great controversy and it took several deca...

Human liver infiltrating γδ T cells are composed of clonally expanded circulating and tissue-resident populations.

γδ T-cells comprise a substantial proportion of tissue-associated lymphocytes. However, our current understanding of human γδ T-cells is primarily based on peripheral blood subsets, while the immu...

The ecology of immune state in a wild mammal, Mus musculus domesticus.

The immune state of wild animals is largely unknown. Knowing this and what affects it is important in understanding how infection and disease affects wild animals. The immune state of wild animals is ...

PD-1 immunobiology in autoimmune hepatitis and hepatocellular carcinoma.

Disruption of liver immune tolerance allows for the development of autoimmune hepatitis (AIH) and hepatocellular carcinoma (HCC). AIH rarely progresses to HCC but the diseases similarly induce the pro...

Evaluation of intranasal and subcutaneous route of immunization in neonatal mice using DODAB-BF as adjuvant with outer membrane vesicles of Neisseria meningitis B.

The Neisseria meningitidis bacterium is a Gram-negative diplococcus that can be classified into different serogroups according to the capsular structure. Six of them (A, B, C, W, X, Y) are responsible...

Clinical Trials [3 Associated Clinical Trials listed on BioPortfolio]

Immunobiology of Cancer

To learn whether or not an Interferon defect in cell signaling, recently discovered in immune cells from melanoma patients as well as breast cancer patients, is common to all cancers.

Immunobiology of Diabetes and Tuberculosis

Despite reports that diabetes mellitus increases the risk of tuberculosis by as much as 11-fold, few studies have focused on the underlying mechanism for this susceptibility. Our ultimate ...

Phase II Clinical Trial: Multi-dosing the BCG Vaccine for Fibromyalgia

The investigators are doing this research study to explore whether the bacillus Calmette-Guérin (BCG) vaccine can be an effective treatment for fibromyalgia. The researchers believe that ...

Companies [87 Associated Companies listed on BioPortfolio]

ImmunoBiology Limited (ImmBio)

Limited [ImmBio] is a biotechnology company specialising in the treatment of infectious diseases and cancer. ImmBio's approach is to apply advances in the emerging science of Immunobiology to the deve...

Microsulis Medical Limited

Founded in 1997, Microsulis Medical Limited is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic d...

Maine Biotechnology Services , Inc.

Since 1990, Maine Biotechnology Services, Inc. has offered a comprehensive range of immunochemicals and contract immunobiology manufacturing services. We focus on contract hybridoma and polyclonal ant...

Immunocore Limited

Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located ...


More Information about "ImmunoBiology Limited (ImmBio)" on BioPortfolio

We have published hundreds of ImmunoBiology Limited (ImmBio) news stories on BioPortfolio along with dozens of ImmunoBiology Limited (ImmBio) Clinical Trials and PubMed Articles about ImmunoBiology Limited (ImmBio) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ImmunoBiology Limited (ImmBio) Companies in our database. You can also find out about relevant ImmunoBiology Limited (ImmBio) Drugs and Medications on this site too.

Quick Search


Relevant Topics

Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Corporate Database Quicklinks

Searches Linking to this Company Record